Daniel Acker

Cofounder & Chief Innovation Officer at Apriori Bio

Daniel Acker has extensive work experience in the field of biotechnology and data sciences. Daniel is currently the Co-founder and Chief Innovation Officer at Metaphore Biotechnologies, a position they have held since February 2021. Prior to this, they co-founded and served as the Chief Innovation Officer at Apriori Bio starting in October 2020.

Before their entrepreneurial ventures, Daniel worked at Flagship Pioneering, where they held various roles. Daniel started as an Associate in May 2020 and later became a Senior Associate in April 2021. Currently, they are a Principal at Flagship Pioneering, a position they have held since March 2023.

Daniel also has experience working as a Scientist in Data Sciences at Repertoire Immune Medicines. In this role, they were involved in building automated analysis pipelines, developing machine learning strategies, and optimizing experimental controls for single-cell assays. Daniel held the position of Scientist II from December 2019 to May 2020 and Scientist from August 2018 to December 2019.

Furthermore, Daniel has worked as a Health Data Science Fellow at Insight Data Science, where they designed a neural network to predict gene expression from DNA sequences.

Earlier in their career, Daniel served as a Graduate Research Assistant at Brandeis University, where they worked on artificial neural networks and epilepsy therapeutics. Daniel also worked as a Data Science Consultant at Upwork, where they developed a Python package, evaluated the effects of a hand hygiene intervention, and cleaned dating website records.

Daniel gained research experience as a Research Assistant at Stony Brook University, where they conducted experiments related to oligodendrocyte proliferation and tissue collection. Daniel also worked as an Undergraduate Research Assistant at Cornell University, contributing to studies on genome insertion frequency and mutagenesis.

Overall, Daniel Acker's work experience showcases their expertise in biotechnology, data sciences, and research. Daniel has played significant roles in various companies and research institutions, demonstrating their ability to innovate and contribute to scientific advancements.

Daniel Acker completed their education in a chronological manner. Daniel started their educational journey in 2009 at Cornell University, where they pursued a Bachelor of Science (BS) degree with distinction in research. Their field of study was focused on Biological Sciences & Animal Science, and they successfully completed this program in 2013.

After completing their undergraduate studies, Daniel Acker joined Brandeis University in 2013 to pursue a Master of Science (MS) degree in Neuroscience. Daniel completed this program in 2014. Following their master's degree, they continued their studies at Brandeis University to pursue a higher academic qualification. From 2014 to 2018, Daniel Acker worked towards achieving a Doctor of Philosophy (PhD) degree in Neuroscience.

In addition to their formal education, Daniel Acker obtained various certifications related to their field. Daniel acquired certifications such as Drug Discovery, Data Science Capstone, Data Science Specialization, Developing Data Products, Practical Machine Learning, Regression Models, Statistical Inference, Reproducible Research, Computational Neuroscience, Exploratory Data Analysis, Getting and Cleaning Data, R Programming, and The Data Scientist's Toolbox. These certifications were attained through Coursera, with specific completion months and years mentioned for each certification.

Overall, Daniel Acker has a strong educational background in Neuroscience, with a focus on both research and practical applications in the field. Additionally, their certifications in data science demonstrate their interest in the intersection of neuroscience and data analysis.

Links

Previous companies

Brandeis University logo
Upwork logo
Repertoire Immune Medicines logo
Cornell University logo
Stony Brook University logo

Timeline

  • Cofounder & Chief Innovation Officer

    October, 2020 - present